First Horizon Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

First Horizon Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$1.6K	Buy	+74	New	+$1.75K	﹤0.01%	2081
2024 Q1	–	Sell	-52	Closed	-$874	–	2303
2023 Q4	$874	Hold	52	–	–	﹤0.01%	2243
2023 Q3	$607	Hold	52	–	–	﹤0.01%	2295
2023 Q2	$698	Hold	52	–	–	﹤0.01%	2338
2023 Q1	$862	Buy	+52	New	+$858	﹤0.01%	2302

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

First Horizon Advisors's CPRX Position: Q2 2025 in Review

First Horizon Advisors opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2025: 74 shares worth $1.6K. The stake represents ﹤0.01% of the portfolio and ranks #2081 among its holdings. This is a return to the name: First Horizon Advisors previously reported a position in CPRX as recently as Q4 2023.

First Horizon Advisors first reported a position in CPRX in Q1 2023 and has held it in 5 quarters since. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

First Horizon Advisors held 74 shares of Catalyst Pharmaceutical worth $1.6K as of Q2 2025.
Catalyst Pharmaceutical was a new First Horizon Advisors position in Q2 2025.
Catalyst Pharmaceutical made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #2081 holding.
First Horizon Advisors first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 5 quarters since.
365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.